EV Biotech

EV Biotech, with the slogan "Accelerating Strain Development," is a microbial cell factory (MCF) strain development company based in The Netherlands. Founded in 2018, the company utilizes state-of-the-art computational modeling and cutting-edge scientific developments in systems biology to create computational models of bacterial strains. This approach enables EV Biotech to predict the most optimal strain modifications, growth media supplementation, and scale-up optimization in line with the rational design strategy, distinguishing itself in the Biotechnology, Food and Beverage, and Nutrition industries. A key differentiator for EV Biotech is the fast-feedback loop between strain modelers and engineers, which enhances the development speed and efficiency of the MCF strain development pipeline. This is further supported by the close collaboration between the theoretical and experimental departments, allowing for quick updates and enhancements to preliminary models when needed. The company's capability to create highly effective compound production strains on demand positions it as an innovative player in the industry. Notably, EV Biotech recently secured a significant €4.50M Seed Round investment on 23 March 2023, with participation from renowned investors including Blue Horizon, NV NOM, Jogchum Brinksma, Hannu Ryopponen, Scott Saxberg, Triade Investment, Carduso Capital, Marc Kaptein, Marie Outtier, and Voyagers. This investment is expected to further fuel the company's growth and innovative endeavors. For more information on EV Biotech's offerings, interested parties are encouraged to contact the company for an offer.